Automated Staining Aids Real-Time Tumor Calls - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Automated Staining Aids Real-Time Tumor Calls

Automated frozen-section staining helped classify selected ambiguous tumors and margins in a single-center validation study.

  • By

  • Andrea Surnit

  • May 11, 2026

  • 3 min

Share

Objective:

To evaluate the effectiveness of fast frozen rapid automated immunohistochemistry (FFRA-IHC) in improving tumor classification during intraoperative assessments, highlighting its potential impact on surgical decision-making.

Key Findings:
  • FFRA-IHC allowed specific classification in 68% of previously unclassifiable tumors, including various tumor types.
  • All 5 ambiguous resection margins were resolved with FFRA-IHC.
  • FFRA-IHC potentially altered intraoperative management in approximately 12% of cases.
  • Turnaround time for FFRA-IHC averaged 21 minutes, with total diagnosis time around 40 minutes.
Interpretation:

FFRA-IHC demonstrates potential to enhance intraoperative decision-making by providing rapid and specific tumor classifications, though its clinical impact needs further validation in broader settings.

Limitations:
  • Small sample size and single-center design limit generalizability.
  • Narrow antibody panel restricted diagnostic scope, impacting findings.
  • Assessment relied on a semiquantitative scoring system not externally validated, affecting reliability.
  • No evaluation of patient outcomes or long-term clinical impact, limiting conclusions.
Conclusion:

Larger studies with expanded antibody panels are needed to assess the broader applicability and clinical outcomes associated with FFRA-IHC in intraoperative pathology, particularly in translating management changes into measurable surgical and oncologic outcomes.

Original Source(s)

Automated Staining Aids Real-Time Tumor Calls

  • by Andrea Surnit

  • May 11, 2026

Related Content

FDA approves combo for ESR1-mutated breast cancer

In an exploratory subgroup analysis of patients with ESR1-mutated tumors, median progression-free survival was 11.1 months with the combination and 5.5 months with imlunestrant alone.

ACS report: Lung cancer deaths plunge as survival doubles

Lung cancer deaths fell by more than half among US males as smoking declined, earlier-stage diagnoses increased, and 5-year relative survival doubled.

NUT carcinoma may defy typical staining patterns

Two pulmonary cases highlight how limited squamous differentiation and variable keratin expression may complicate pathological diagnosis.